CLICK HERE FOR IMFINZI PRODUCT INFORMATION

BTC HOME / VIDEO

VIDEOS

INTERNATIONAL EXPERT INSIGHTS

A series of short interviews with Professor Arndt Vogel

Toronto General Hospital; Princess Margaret Cancer Centre, Toronto, Canada

Professor Vogel has authored more than 250 journal articles on hepatobiliary cancers and precision medicine. He is also the coordinator of the ESMO Clinical Practice Guideline on the management of hepatocellular carcinoma and BTC.

Changes to the BTC treatment landscape and international guidelines

Can you comment on the recent changes to the international guidelines?
How has the BTC landscape evolved in recent years?
What factors do you consider when choosing an immunotherapy for your patients living with BTC?

TOPAZ Phase III trial design and results

Can you tell us about the TOPAZ-1 trial?
What are the key benefits of the IMFINZI TOPAZ-1 regimen?
Do you have a recent patient case that you could share?

Patient-centred experience

In your practice how have patients benefited from IMFINZI?
Which patients are suitable for IMFINZI? Are there any subgroups that are unsuitable?
What do you tell your patients about IMFINZI and what to expect from their treatment?

Speak to an AstraZeneca representative about IMFINZI for BTC

IMFINZI
IMFINZI

PLEASE CLICK HERE TO REVIEW FULL PRODUCT INFORMATION BEFORE PRESCRIBING.
FURTHER INFORMATION AVAILABLE ON REQUEST FROM ASTRAZENECA ON 1800 805 342.

PBS INFORMATION: Authority Required (STREAMLINED). Refer to PBS schedule for full information.

SUBSCRIBE TO ASTRAZENECA COMMUNICATIONS

BTC, biliary tract cancer; ESMO, European Society for Medical Oncology; gem-cis, gemcitabine-cisplatin.

Reference: 1. IMFINZI® Approved Product Information.

IMFINZI® is a registered trademark of the AstraZeneca group of companies. Registered user AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. www.astrazeneca.com.au. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone 1800 805 342 or via https://contactazmedical.astrazeneca.com. 

IMFINZI
IMFINZI

PBS Information: Authority required (STREAMLINED) for NSCLC. Refer to PBS Schedule for full authority information.

PLEASE CLICK HERE TO REVIEW FULL PRODUCT INFORMATION BEFORE PRESCRIBING.
FURTHER INFORMATION AVAILABLE ON REQUEST FROM ASTRAZENECA ON 1800 805 342.

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

AE: adverse event; BICR: Blinded Independent Central Review; CI: confidence interval; CRT: chemoradiation therapy; HR: hazard ratio; irAE: immune-related adverse event; NSCLC: non-small cell lung cancer; OS: overall survival; PFS: progression-free survival; RECIST: Response Evaluation Criteria in Solid Tumors.

References: 1. Girard N, et al. J Thorac Oncol 2023;18:181-193. 2. Spigel DR, et al. J Clin Oncol 2022;1301-1311. 3. Antonia SJ, et al. N Engl J Med 2017;377:1919-1929. IMFINZI® is a registered trademark of the AstraZeneca group of companies. Registered user AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. https://www.astrazeneca.com.au. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone 1800 805 342 or via https://contactazmedical.astrazeneca.com or email Medical Information enquiries to medinfo.australia@astrazeneca.com. AU-15640 ASTR0828/EMBC Date of preparation: January 2023.
SUBSCRIBE TO ASTRAZENECA COMMUNICATIONS